Study of romiplostim for low platelets after radiation therapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called romiplostim N01 to see if it can increase low platelet counts caused by radiation therapy or radiation combined with other cancer treatments. Platelets help your blood clot, and low levels can be dangerous.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with a solid tumor cancer (like lung, breast, or nasopharyngeal cancer).
- You have received radiation therapy (at least 45 Gy) for at least 2 weeks, alone or with chemo or other treatments.
- Your platelet count is below 75 and you are still in or within one month of finishing radiation.
- Your doctor expects you to live at least 12 more weeks and you are able to do daily activities (ECOG score 0-2).
- You are not pregnant, not breastfeeding, and will use birth control during the study and for 6 months after.
- You have not taken certain other platelet-raising medicines recently or participated in other drug trials in the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a medicine called Romiplostim N01 to help raise platelet levels in people with solid tumors who have low platelets from chemo, radiation, or immunotherapy. The goal is to see if it can safely improve platelet counts so patients can continue their cancer treatment.
This trial tests a new form of romiplostim (a drug that boosts platelets) in breast cancer patients whose platelet counts have dropped due to chemotherapy. It aims to see if it can safely raise platelet levels to reduce bleeding risk and allow chemo to continue.
This trial tests a new drug called Romiplostim N01 to see if it works better than the standard treatment (recombinant human thrombopoietin) for raising low platelets caused by cancer therapies, when other treatments have failed. It is for people aged 18-75 with solid tumors or blood cancers who have not responded to at least two platelet growth factors.
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.